Anixa Biosciences treats sixth patient in ovarian cancer CAR-T clinical trial

Anixa Biosciences announced that it has treated the sixth patient in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell therapy for ovarian cancer. This patient is expected to be the last patient in the second dosage cohort. If there continue to be no adverse effects experienced by the second cohort participants, enrollment of the third dosage cohort may commence within the next month. The study is being conducted through a research partnership with Moffitt Cancer Center.